Intracranial stents are used for intracranial stenosis and brain aneurysms to open the blocked arteries. This procedure is relatively new for these conditions and long-term enhanced results for placement of these stents alone is still under investigation. However, various studies accepted the potential of placement of stents to reduce the risk of stroke in patients with symptomatic intracranial stenosis as compared to medical therapy alone. Thus, boosting the growth of the market over the forecast period in various regions discussed in detail below under the segmentation.Market DynamicsFactors such as increasing prevalence of brain aneurysms and stroke, government programs to decrease the burden of traumatic brain injury, technological advancements plugging treatment gaps and availability of reimbursement are propelling demand for intracranial stents. However, high cost and stringent government regulations is negatively impacting growth of the market. Companies are therefore, adopting different strategies such as providing FDA approved on-site training, strategic collaborations, and technology upgrades in order to increase their market presence and engage with customers. For instance, in January 2018, Stryker announced the positive results of WEAVE, the post market surveillance study of the company's Wingspan stent system, for the patients suffering from intracranial atherosclerotic disease (ICAD). Thus, providing more opportunities in procedural approach with significant results.
Intracranial stents are used for intracranial stenosis and brain aneurysms to open the blocked arteries. This procedure is relatively new for these conditions and long-term enhanced results for placement of these stents alone is still under investigation. However, various studies accepted the potential of placement of stents to reduce the risk of stroke in patients with symptomatic intracranial stenosis as compared to medical therapy alone. Thus, boosting the growth of the market over the forecast period in various regions discussed in detail below under the segmentation.Market DynamicsFactors such as increasing prevalence of brain aneurysms and stroke, government programs to decrease the burden of traumatic brain injury, technological advancements plugging treatment gaps and availability of reimbursement are propelling demand for intracranial stents. However, high cost and stringent government regulations is negatively impacting growth of the market. Companies are therefore, adopting different strategies such as providing FDA approved on-site training, strategic collaborations, and technology upgrades in order to increase their market presence and engage with customers. For instance, in January 2018, Stryker announced the positive results of WEAVE, the post market surveillance study of the company's Wingspan stent system, for the patients suffering from intracranial atherosclerotic disease (ICAD). Thus, providing more opportunities in procedural approach with significant results.